{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:09:54Z","timestamp":1788865794566,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>\n                    <jats:bold>Background\/objective<\/jats:bold>\n                    : Kawasaki disease is an acute, systemic vasculitis most commonly observed in young Asian children. While the exact pathogenesis remains unknown, it is thought to be triggered by a pathogenic exposure that elicits an inflammatory response several days to 2 weeks before the onset of symptoms. Symptoms include edematous hands and feet, conjunctivitis, mucositis, a diffuse erythematous rash, lymphadenopathy, and a fever lasting for at least 5 days, which is required for diagnosis. In addition, coronary vessels may exhibit aneurysms, thrombosis, and stenosis. Without treatment, Kawasaki disease carries a 25% risk of developing coronary aneurysms. However, with the timely administration of intravenous immunoglobulin, this risk is reduced to 4%. Given the inflammation and possible thrombosis of the coronary vasculature, current guidelines recommend aspirin for the management of Kawasaki disease. Kawasaki disease is one of the few conditions in which administering aspirin to children is considered acceptable, despite the risk of inducing Reye syndrome, a potentially fatal condition triggered by a viral infection while taking salicylates such as aspirin. Therefore, this review addresses a key question: why continue to use aspirin with its known risk of Reye syndrome when alternative antithrombotic drugs used in pediatric patients are available? This review seeks to explore potential substitutes for aspirin to mitigate the risk of Reye syndrome while also providing the necessary anticoagulation in Kawasaki disease.\n                  <\/jats:p>","DOI":"10.3389\/fped.2026.1856121","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:36:31Z","timestamp":1788863791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential alternatives in treatment of kawasaki disease to reduce the extremely rare risk of reye syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Ethan J.","family":"Johnson","sequence":"first","affiliation":[{"name":"College of Medicine, Northeast Ohio Medical University","place":["Rootstown, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Moser","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, University of North Dakota","place":["Grand Forks, ND, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Buehrer","sequence":"additional","affiliation":[{"name":"College of Medicine, Northeast Ohio Medical University","place":["Rootstown, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khiet","family":"Ngo","sequence":"additional","affiliation":[{"name":"College of Medicine, Northeast Ohio Medical University","place":["Rootstown, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Raina","sequence":"additional","affiliation":[{"name":"College of Medicine, Northeast Ohio Medical University","place":["Rootstown, OH, United States"]},{"name":"Department of Nephrology, Akron Nephrology Associates\/Cleveland Clinic Akron General Medical Center","place":["Akron, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1017\/S104795112500191X","article-title":"Global incidence of Kawasaki disease: a systematic review","volume":"35","author":"Kang","year":"2025","journal-title":"Cardiol Young"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","article-title":"Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association","volume":"150","author":"Jone","year":"2024","journal-title":"Circulation"},{"key":"B4","article-title":"Kawasaki disease: Initial treatment and prognosis","volume-title":"UpToDate","author":"Son","year":"2026"},{"key":"B5","first-page":"67","article-title":"Kawasaki disease with Reye syndrome: report of one case","volume":"33","author":"Lee","year":"1992","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi"},{"key":"B6","first-page":"185","article-title":"Reye\u2019s syndrome arising from the treatment of Kawasaki disease","volume":"23","author":"Su","year":"2018","journal-title":"HK J Paediatr"},{"key":"B7","first-page":"436","article-title":"Reye syndrome following Kawasaki syndrome confirmed by liver histopathology","volume-title":"Kawasaki Disease: Proceedings of the 5th International Kawasaki Disease Symposium, 22\u201325 May 1995, Fukuoka, Japan","author":"Takahashi","year":"1995"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/1756-185X.13213","article-title":"Is Kawasaki disease an infectious disorder?","volume":"21","author":"Rowley","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41584-020-0426-0","article-title":"Kawasaki disease: pathophysiology and insights from mouse models","volume":"16","author":"Noval Rivas","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7952","DOI":"10.1073\/pnas.1400380111","article-title":"Tropospheric winds from Northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan","volume":"111","author":"Rod\u00f3","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/ng.2007.59","article-title":"ITPKC Functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms","volume":"40","author":"Onouchi","year":"2008","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e17370","DOI":"10.1371\/journal.pone.0017370","article-title":"ITPKC Single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population","volume":"6","author":"Kuo","year":"2011","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.micinf.2009.04.008","article-title":"The calcium\/NFAT pathway: role in development and function of regulatory T cells","volume":"11","author":"Oh-hora","year":"2009","journal-title":"Microbes Infect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0145486","DOI":"10.1371\/journal.pone.0145486","article-title":"Variations in ORAI1 gene associated with Kawasaki disease","volume":"11","author":"Onouchi","year":"2016","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e3000722","DOI":"10.1371\/journal.pbio.3000722","article-title":"NCX1 Represents an ionic Na+ sensing mechanism in macrophages","volume":"18","author":"Neubert","year":"2020","journal-title":"PLoS Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1161\/CIRCGENETICS.116.001533","article-title":"Genetic variation in the SLC8A1 calcium signaling pathway is associated with susceptibility to Kawasaki disease and coronary artery abnormalities","volume":"9","author":"Shimizu","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e38998","DOI":"10.1371\/journal.pone.0038998","article-title":"Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study","volume":"7","author":"Orenstein","year":"2012","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e002433","DOI":"10.1161\/CIRCGEN.118.002433","article-title":"Circulating markers of inflammation persist in children and adults with giant aneurysms after Kawasaki disease","volume":"12","author":"Lech","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2165\/00003088-198510020-00004","article-title":"Clinical pharmacokinetics of the salicylates","volume":"10","author":"Needs","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jth.12472","article-title":"Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation","volume":"12","author":"Capra","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e60659","DOI":"10.7759\/cureus.60659","article-title":"Effects of low and high doses of aspirin on inflammatory markers in diabesity patients: a quasi-experimental study","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17425255.2024.2386368","article-title":"Pharmacokinetics of aspirin: evaluating shortcomings in the literature","volume":"20","author":"Visagie","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.15406\/jpnc.2022.12.00469","article-title":"Etiology, pathophysiology and management of Reye\u2019s syndrome","volume":"12","author":"Bereda","year":"2022","journal-title":"J Pediatr Neonatal Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/dmcn.12717","article-title":"Impact of fatty acid oxidation disorders in child neurology: from Reye syndrome to Pandora\u2019s box","volume":"57","author":"Tein","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.1038\/s41598-020-66251-y","article-title":"An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms","volume":"10","author":"Poolchanuan","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.5281\/zenodo.17671515","article-title":"The role of antiplatelet agents in clinical practice: mechanism of action, indications, limitations, and future directions\u2014a comprehensive review","volume":"3","author":"Venkatesh","year":"2025","journal-title":"Int J Pharm. Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1441-2772(23)00390-3","article-title":"Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial","volume":"22","author":"Cioccari","year":"2020","journal-title":"Crit Care Resusc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bbi.2024.07.023","article-title":"Effects of low-dose acetylsalicylic acid on the inflammatory response to experimental sleep restriction in healthy humans","volume":"121","author":"Engert","year":"2024","journal-title":"Brain Behav Immun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.3390\/diagnostics13142338","article-title":"Evolution and pathogenic mechanisms","volume":"13","author":"Nadig","year":"2023","journal-title":"Diagnostics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","article-title":"Kawasaki disease","volume":"67","author":"Newburger","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B31","article-title":"Reye syndrome","volume-title":"StatPearls [Internet]","author":"Chapman","year":"2026"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJM199905063401801","article-title":"Reye\u2019s syndrome in the United States from 1981 through 1997","volume":"340","author":"Belay","year":"1999","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14776\/kjpid.2012.19.2.79","article-title":"A case of Reye syndrome following treatment of Kawasaki disease with aspirin","volume":"19","author":"Lee","year":"2012","journal-title":"Korean J Pediatr Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.21037\/tp-21-74","article-title":"Effectiveness and safety of dual antiplatelet therapy in coronary aneurysms caused by Kawasaki disease in children: study protocol for a multicenter randomized clinical trial","volume":"10","author":"Li","year":"2021","journal-title":"Transl Pediatr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis","volume":"99","author":"Chen","year":"2013","journal-title":"Heart"},{"key":"B36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/ped.12317","article-title":"Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version)","volume":"56","year":"2014","journal-title":"Pediatr Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.7499\/j.issn.1008-8830.2406041","article-title":"\u56fd\u5185\u5916\u5ddd\u5d0e\u75c5\u6307\u5357\u7684\u5f02\u540c\u70b9\u89e3\u8bfb [Interpretation of similarities and differences in Kawasaki disease guidelines at home and abroad]","volume":"27","author":"Pan","year":"2025","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e253063","DOI":"10.1001\/jamanetworkopen.2025.3063","article-title":"Intravenous immunoglobulin alone for coronary artery lesion treatment of Kawasaki disease: a randomized clinical trial","volume":"8","author":"Kuo","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/clinpract14040105","article-title":"The effectiveness of no or low-dose versus high-dose aspirin in treating acute Kawasaki disease: a systematic review and meta-analysis","volume":"14","author":"Safar","year":"2024","journal-title":"Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","article-title":"Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial","volume":"379","author":"Kobayashi","year":"2012","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/jpids\/piae112","article-title":"Primary adjunctive corticosteroids in the acute management of high-risk Kawasaki disease in a North American cohort","volume":"13","author":"Wang","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"18324","DOI":"10.1038\/s41598-023-45647-6","article-title":"The safety and effectiveness of clopidogrel versus aspirin in Kawasaki disease with mild-to-moderate liver injury","volume":"13","author":"Gao","year":"2023","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.freeradbiomed.2013.06.007","article-title":"Hepatocellular toxicity of clopidogrel: mechanisms and risk factors","volume":"65","author":"Zahno","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e71950","DOI":"10.1002\/hsr2.71950","article-title":"Potential effects of aspirin on transcription factors related to the inflammation in atherosclerosis: a systematic review","volume":"9","author":"Aghaei","year":"2026","journal-title":"Health Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1114588","article-title":"Clopidogrel in infants with systemic-to-pulmonary-artery shunts","volume":"368","author":"Wessel","year":"2013","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/a-2486-6735","article-title":"The use of DOACs in pediatrics: current therapeutic and prophylactic indications, cardiac indications, and real-world evidence-A review","volume":"45","author":"Bosch","year":"2025","journal-title":"Hamostaseologie"},{"key":"B49","article-title":"Direct oral anticoagulants for thromboembolism in pediatrics","volume":"41","author":"Goldenberg","year":"2025","journal-title":"Contemp Pediatr"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"B52","volume-title":"Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease: A Multicenter, Open-Label, Parallel, Exploratory, Randomized Controlled Trial","year":"2025"},{"key":"B53","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1017\/S1047951123003761","article-title":"Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis","volume":"34","author":"Sagiv","year":"2024","journal-title":"Cardiol Young"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1856121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:36:34Z","timestamp":1788863794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1856121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":54,"alternative-id":["10.3389\/fped.2026.1856121"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1856121","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1856121"}}